“和调督任安神法”治疗轻中度抑郁症的临床随机对照观察

目的观察“和调督任安神法”治疗轻中度抑郁症的临床疗效。方法将该院门诊105例轻中度抑郁症患者按随机数字表法分为观察组(52例,脱落1例)和对照组(53例,脱落2例)。观察组采用“和调督任安神法”治疗,对照组采用常规针刺治疗,二者均治疗4周,治疗前后分别进行抑郁自评量表(SDS)、汉密尔顿抑郁量表(HAMD)及生存质量测定量表(WHOQOL-BREF)评分,并比较临床疗效。于治疗结束6个月后观察其复发情况。结果观察组临床疗效总有效率为94.41%(48/51),对照组为72.55%(37/51),观察组优于对照组(P<0.05)。两组患者治疗后HAMD评分、SDS评分与治疗前比,均明显降低(P<0.05),两组WHOQOL-BREF评分与治疗前比均明显提高(P<0.05),且观察组优于对照组(P<0.05)。6个月后随访时,HAMD评分、SDS评分、WHOQOL-BREF量表评分较治疗后均明显改善(P<0.05),且观察组优于对照组(P<0.05)。结论“和调督任安神法”能改善轻中度抑郁症患者的临床症状生存质量,有效地提高轻中度抑郁症患者的临床疗效,具有推广价值。

Clinical observation in three-dimensional conformal radiotherapy (3D-CRT) with concurrent chemotherapy in treatment of postoperative cerebral gliomas

Objective:The aim of the study was to investigate the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with Temozolomide (TMZ) concurrent chemotherapy in treatment of postoperative cerebral gliomas by prospective randomized controlled trials. Methods: Sixty-two patients with cerebral glioma who had residual tumor were divided into 3D-CRT group (radiotherapy group, n=31) and 3D-CRT with concurrent chemotherapy group (chemoradiotherapy group, n=31) prospectively. All patients received a dose of 50-60 Gy/25-30 F/5-6 weeks by 6 MV-X ray, three-dimensional conformal radiotherapy, 1 f/d, 5 times a week. Chemotherapy regimen was Temozolomide:75 mg/m2/d, concomitantly with radiotherapy, followed by 150-200 mg/m2/d, 5 days, 28 days per cycle, totally 3-6 cycles. Results: The total response rate was 35.3% (11/31) in radiotherapy group. The response rate was 61.3% (19/31) in chemoradiotherapy group. There was significant difference in curative effect (P=0.042). There was no significant difference in survival comparison of two groups (P=0.263). Stratified analysis showed the patients with grade Ⅲ gliomas of chemoradiotherapy group had better prognosis than ones of radiotherapy group (P=0.043). Conclusion: The 3D-CRT with concurrent chemotherapy can improve the survival of cerebral gliomas with pathological grade Ⅲ.

A＋C群脑膜炎球菌多糖疫苗安全性评估

目的 评估A＋C群脑膜炎球菌多糖疫苗的安全性。方法 以A＋C群脑膜炎球菌多糖疫苗为观察组，伤寒Vi多糖疫苗为对照组，按整群随机分层配对的原则，将研究现场分为108个组群，观察组和对照组各分配54个组。对两组同时建立接种反应监测系统，按统一表格和方法对两组的接种反应进行监测、记录，并进行流行病学调查。结果 两组共接种34543人，其中A＋C群脑膜炎球菌多糖疫苗接种18167人，伤寒Vi疫苗接种16376人。A＋C群脑膜炎球菌多糖疫苗速发接种反应率为0．44‰，一般接种反应率为0．38％o；伤寒Vi疫苗速发接种反应率为0．79％，一般接种反应率为0．73％o；跟踪随访接种反应对象共1239人，其中接种A＋C群脑膜炎球菌多糖疫苗的771人，接种伤寒Vi疫苗的468人。接种后第1天，A＋C群脑膜炎球菌多糖疫苗组的局部反应发生率要明显高于伤寒Vi疫苗（X^2。=13．98，P=0．0002）；接种后第2—3天局部反应和全身反应的发生率，两组差异无统计学意义；两组各自接种人群和未接种人群发热发生率的差异无统计学意义，两组已接种人群的发热发生率差异也无统计学意义；两组均未发现严重反应。结论 A＋C群脑膜炎球菌多糖疫苗与伤寒Vi疫苗均可在不同年龄组人群开展大规模接种，局部及全身接种反应轻微，接种反应率低，有良好的安全性。